New combo therapy aims to shrink inoperable pancreatic tumors
NCT ID NCT02207465
First seen Nov 19, 2025 · Last updated May 12, 2026 · Updated 21 times
Summary
This early-phase study tests whether giving a higher dose of radiation along with the chemotherapy drug nab-paclitaxel can better control pancreatic cancer that cannot be removed by surgery. About 42 adults with locally advanced or borderline resectable pancreatic cancer will receive this combination. The main goal is to find the safest dose and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER TREATED WITH CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Chester County Hospital
West Chester, Pennsylvania, 19380, United States
Conditions
Explore the condition pages connected to this study.